The House Voted to Schedule Xylazine. The Drug That Replaced It Sends People to the ICU.

A 31-year-old woman, interviewed in a hospital by University of Pittsburgh researchers last fall, described what the sedative in her fentanyl does to a person in one sentence. It will knock you out no matter what, you couldn’t even fight it. She was one of 16 adults with opioid use disorder, hospitalized between September and November 2025 after confirmed exposure to medetomidine, who sat for interviews that the Annals of Internal Medicine published in September. They described a drug they could not avoid, and a body that went down in public places where robbery and assault were waiting.

The bill the House of Representatives passed on September 15 changes that drug’s legal schedule. It does not change what happens to people like her.

Banning one sedative in the fentanyl supply does not take sedatives out of the fentanyl supply. It picks the next one.

If you use fentanyl and the sedation has felt different over the last year or so, heavier, longer, a nod you could not shake, you noticed something real. This piece, part of our harm reduction and novel and emerging substances coverage, is about why that happened, why the law now moving through Congress is aimed at the drug that was already leaving, and what is still yours to reach for tonight.

The ban moved the sedation, not the sedative

Xylazine, the veterinary tranquilizer people call tranq, is what Congress is trying to schedule. The Combating Illicit Xylazine Act, H.R. 1266, would place illicit xylazine in Schedule III of the Controlled Substances Act, which makes non-veterinary possession, manufacture and distribution a federal crime. It passed the House on September 15. It is not law: it still needs the Senate and a signature, so nothing on the street changes because of it yet.

The reason to doubt it will do what its supporters want is already on the books in fourteen states. David Zhu, an MD/PhD candidate at Virginia Commonwealth University, and Sehun Oh, an associate professor at Ohio State, compared nine states that scheduled xylazine with five that criminalized it without scheduling, using 1999 to 2025 lab-seizure records from the federal National Forensic Laboratory Information System. Across the whole period that system logged 101,987 xylazine reports and 12,085 medetomidine reports. The results, in the International Journal of Drug Policy: scheduling was not associated with a significant change in xylazine reports, and it was associated with roughly 1,537 additional medetomidine reports per 100,000 lab reports (95% confidence interval, 211 to 2,862, as Healio reported).

Read that last number with its limits attached. The interval is wide: the true effect could be small or very large. These are lab reports, which track what police and labs happen to submit, not what is in any one person’s body. And a comparison of 14 states cannot prove scheduling caused the shift. Zhu says his own team’s work is the first to examine this for xylazine and medetomidine, and he is blunt about what it suggests: “our findings provide a cautionary tale against these supply-side drug control policies.”

The street-level picture matches. In Philadelphia, CDC investigators found medetomidine in 72% of illegal opioid samples in late 2024 while xylazine fell from 98% to 31%. In North Carolina, the UNC Street Drug Analysis Lab, which has logged more than 23,000 submissions, says medetomidine overtook xylazine in early 2026. Pennsylvania made xylazine Schedule III in May 2024, and the same reporting says medetomidine is now more common than fentanyl in Pittsburgh’s supply. Elyse Powell, who directs the North Carolina Harm Reduction Coalition and serves more than 5,000 people a year, put the pattern in two sentences: “Every time they schedule one of these new things, it’s just replaced with something else, and more often than not, that something else is worse.”

In North Carolina, the UNC Street Drug Analysis Lab, which has logged more than 23,000 submissions, says medetomidine overtook xylazine in early 2026.

What the hospital sees that the roadside never will

Medetomidine is a sedative in the same family as xylazine. Neither is an opioid. Both work by turning down the body’s alarm system, which slows the heart and drops blood pressure, and both ride along with fentanyl. Naloxone can reverse the fentanyl. It does nothing to the sedative, so a person can start breathing again and stay heavily sedated, which is why the woman in the Pittsburgh interviews talked about not being able to fight it.

The cost shows up when the drug stops. In the CDC’s report on 165 patients at three Philadelphia health systems between September 2024 and January 2025, 91% needed intensive care and 24% needed a breathing tube. The median peak heart rate was 145 beats a minute and the median peak systolic blood pressure was 195. The usual toolkit failed: escalating opioids, sedatives, clonidine, ketamine and olanzapine did not control it, and vomiting made oral clonidine hard to keep down. What worked was dexmedetomidine, an ICU sedative from the same drug family, given by infusion, and 83% of patients responded to it.

Nabarun Dasgupta, who directs the UNC lab, told a House Energy and Commerce subcommittee in written testimony on March 26 that medetomidine withdrawal “is unlike anything most emergency physicians have seen before”. It can start within hours of the last use and can mean weeks in intensive care. Zhu is more direct about what that does to a hospital: “Many patients may need to be escalated to higher levels of care, including ICU-level stabilization.”

Here is what the interview study adds that a lab report cannot. The 16 patients described standard opioid use disorder medications that often did not touch what they were feeling, and they described the loss of control as the dangerous part. The study is small, it only reached people who made it to a hospital, and it cannot say how common severe withdrawal is. But it names a risk that a seizure statistic never will: a person who cannot choose to stay awake is a person who gets robbed on a sidewalk.

For providers, this is a this-week problem, not a legislative one. Ask your emergency department and your detox team three questions at the next huddle. Does anyone on staff recognize medetomidine withdrawal, meaning a racing heart, severe hypertension and vomiting that standard anti-nausea drugs do not touch? Do you have a transfer agreement with a hospital that can run a dexmedetomidine infusion? And does your intake ask patients, in plain words, whether the sedation or the crash has changed in the last year? Case managers can add one line to a handoff: tell the hospital the person uses fentanyl, because the pattern is different from what ER staff were trained to expect.

A bill built for the last drug

Drug laws have a habit of arriving after the market has already left the room. In 1920 the United States banned alcohol, and the market did what drug-policy researchers call the iron law of prohibition: because bulk is risky to move, beer faded and distilled spirits, which pack more punch per smuggled bottle, took over. Stronger products win when the law punishes the weaker ones. The same loop shows up in modern chemistry, Zhu says: fentanyl-related compounds were scheduled in 2017 and 2018, and nitazenes arrived; nitazenes were scheduled in July 2025, and what he calls “orphines” followed. Each round, medicine starts from zero on the new compound. Zhu notes that “there’s a timely need for evidence-based guidelines, especially around withdrawal,” because for medetomidine there are none yet.

That last point is where the money goes wrong. Fentanyl test strips cost about $35 for a box of 100. Strips for medetomidine run about $200 a box, and Zhu’s first recommendation is not a penalty but “to ensure access to harm reduction-informed drug checking services,” with state opioid settlement money filling the funding gap. R Street’s Stacey McKenna, writing October 19, reaches the same place from a different political direction: prioritize easier access to medications for opioid use disorder, naloxone and test strips over bans. The case that bans “help law enforcement” is real, and the evidence that they reduce the sedatives people actually encounter is, so far, thin.

The case that bans “help law enforcement” is real, and the evidence that they reduce the sedatives people actually encounter is, so far, thin.

None of this means the news is only bad. The CDC’s August 31 data release counted 67,798 predicted overdose deaths in the 12 months ending March 2026, 12.3% fewer than a year earlier, and the people who got us there did it with naloxone, medications and access, not with new schedules.

So here is what is still yours, tonight. Naloxone still works on the fentanyl these sedatives travel with, and carrying it is still worth it. A hospital can treat this withdrawal, and the 83% response rate to dexmedetomidine is the reason to go instead of white-knuckling it at home: if you stop and the crash hits, say what you were using and say it first. Drug checking is still how you find out what is in your supply. And the people who run the coalition vans are still there.

The woman in Pittsburgh did not ask for a better statute. She told the researchers that the drug knocks you out no matter what and you can’t even fight it. A law that renames a drug cannot answer that sentence. A strip in your pocket, a nurse who knows the pattern, and a bed with the right infusion can. That sentence is the whole policy brief.